Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Callanan

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
The New England Journal of Medicine|September 28, 2017
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell LymphomaSteven Le Gouill, Catherine Thieblemont, Lucie Oberic, et al.
Blood Cancer Journal|April 24, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA studyClémentine Sarkozy, Loïc Chartier, Vincent Ribrag, et al.
Journal of Clinical Immunology|May 8, 2012
Clinical, functional and genetic analysis of twenty-four patients with chronic granulomatous disease - identification of eight novel mutations in CYBB and NCF2 genesCécile Martel, Michelle Mollin, Sylvain Beaumel, et al.
Haematologica|November 30, 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA groupSylvain Carras, Alexia Torroja, Anouk Emadali, et al.
Blood Advances|December 24, 2019
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?Francine Garnache-Ottou, Chrystelle Vidal, Sabeha Biichlé, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
The New England Journal of Medicine|September 28, 2017
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell LymphomaSteven Le Gouill, Catherine Thieblemont, Lucie Oberic, et al.
Blood Cancer Journal|April 24, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA studyClémentine Sarkozy, Loïc Chartier, Vincent Ribrag, et al.
Journal of Clinical Immunology|May 8, 2012
Clinical, functional and genetic analysis of twenty-four patients with chronic granulomatous disease - identification of eight novel mutations in CYBB and NCF2 genesCécile Martel, Michelle Mollin, Sylvain Beaumel, et al.
Haematologica|November 30, 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA groupSylvain Carras, Alexia Torroja, Anouk Emadali, et al.
Blood Advances|December 24, 2019
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?Francine Garnache-Ottou, Chrystelle Vidal, Sabeha Biichlé, et al.
Pageof 4